Results 1 to 10 of about 85,807 (290)

CD86 regulates myeloma cell survival [PDF]

open access: yesBlood Advances, 2017
: Although prognosis for patients with multiple myeloma has improved over the past decade, research toward discovery of new therapeutic avenues is important and could lead to a cure for this plasma cell malignancy.
Catherine M. Gavile   +7 more
doaj   +4 more sources

Longitudinal Change in CD86 Expression Is Associated with Regression of Cervical Intraepithelial Neoplasia [PDF]

open access: yesBiomedicines
Background/Objectives: Cervical intraepithelial neoplasia (CIN) exhibits heterogeneous clinical behavior, with some lesions regressing spontaneously, whereas others persist or progress to higher-grade disease.
Rina Kawatake   +14 more
doaj   +3 more sources

CD86 in Dendritic Cell-Mediated Cancer Immunity: From Maturation Marker to Functional Regulator [PDF]

open access: yesBiomedicines
Dendritic cell (DC)-based cancer immunotherapy remains limited by heterogeneous immune responses and variable clinical efficacy. CD86, a key co-stimulatory molecule, is traditionally regarded as a marker of dendritic cell maturation; however ...
Ting-Wei Wu, Chu-Hsin Chuang, Yi-Hui Wu
doaj   +3 more sources

CD86 is linked to apoptosis in canine histiocytic sarcoma

open access: yesFrontiers in Veterinary Science
Immune checkpoints are critical for the regulation of tumor growth and regression. Recently an effect of CD80 and CD86 on tumor regression in canine cutaneous histiocytoma has been described.
Benjamin Diehl   +2 more
doaj   +3 more sources

Expression of pro-inflammatory and co-stimulatory molecules on the surface of macrophages in vitro in patients with pulmonary tuberculosis

open access: yesБюллетень сибирской медицины, 2021
The aim of this study was to identify features of the expression of pro-inflammatory and co-stimulatory molecules on the surface of macrophages in vitro in patients with pulmonary tuberculosis, depending on the clinical form of the disease and ...
E. G. Churina   +6 more
doaj   +1 more source

Prohibitins and the Cytoplasmic Domain of CD86 Cooperate To Mediate CD86 Signaling in B Lymphocytes [PDF]

open access: yesThe Journal of Immunology, 2013
Abstract CD86 engagement on a CD40L/IL-4–primed murine B cell activates signaling intermediates that promote NF-κB activation to increase Oct-2 and mature IgG1 mRNA and protein expression, as well as the rate of IgG1 transcription, without affecting class switch recombination.
Christopher R, Lucas   +7 more
openaire   +3 more sources

Immuno-phenotyping of IDH-mutant grade 3 astrocytoma and IDH-wildtype glioblastoma reveals specific differences in cells of myeloid origin

open access: yesOncoImmunology, 2021
Gliomas are heavily infiltrated with immune cells of myeloid origin. Past studies have shown that high-grade gliomas have a higher proportion of alternatively activated and suppressive myeloid cells when compared to low-grade gliomas, which correlate ...
Jayashree V. Raghavan   +14 more
doaj   +1 more source

Integrated Analysis Reveals Prognostic Value and Immune Correlates of CD86 Expression in Lower Grade Glioma

open access: yesFrontiers in Oncology, 2021
BackgroundCD86 has great potential to be a new target of immunotherapy by regulating cancer immune response. However, it remains unclear whether CD86 is a friend or foe in lower-grade glioma (LGG).MethodsThe prognostic value of CD86 expression in pan ...
Huaide Qiu   +9 more
doaj   +1 more source

CD86+/CD206+ tumor-associated macrophages predict prognosis of patients with intrahepatic cholangiocarcinoma [PDF]

open access: yesPeerJ, 2020
Background As the main cellular ingredients of tumor microenvironment, tumor-associated macrophages (TAMs) play a vital role in tumor development and progression.
Dalong Sun   +8 more
doaj   +2 more sources

The Ratio of CD86+/CD163+ Macrophages Predicts Postoperative Recurrence in Stage II-III Colorectal Cancer

open access: yesFrontiers in Immunology, 2021
Tumor-associated macrophages (TAMs) are pivotal for tumor progression and metastasis. We investigated the stromal CD86+TAM/CD163+TAM (CD86/CD163) ratio as a novel prognostic biomarker for stage II-III colorectal cancer (CRC).
Guozeng Xu   +6 more
doaj   +1 more source

Home - About - Disclaimer - Privacy